ID

31074

Beschrijving

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE); ODM derived from: https://clinicaltrials.gov/show/NCT00719472

Link

https://clinicaltrials.gov/show/NCT00719472

Trefwoorden

Versies (1)
  1. 18-07-18 18-07-18 -
Houder van rechten

See clinicaltrials.gov

Geüploaded op

18 juli 2018

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Non-Hodgkin's Lymphoma NCT00719472

Engels

Eligibility Non-Hodgkin's Lymphoma NCT00719472

1 Formulieren  
Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
written informed consent
Beschrijving

Informed Consent

Datatype

boolean

Alias
UMLS CUI [1]
C0021430
age ≥ 18 years
Beschrijving

Age

Datatype

boolean

Alias
UMLS CUI [1]
C0001779
patients with previously untreated diffuse large b-cell lymphoma (dlbcl) who are scheduled to receive rituximab 375 mg/m^2 plus chop (cyclophosphamide, hydroxydaunorubicin [also called doxorubicin or adriamycin], oncovin [vincristine], prednisone or prednisolone) chemotherapy, or previously untreated follicular non-hodgkin lymphoma (nhl) who are scheduled to receive rituximab 375 mg/m^2 plus cvp (cyclophosphamide, vincristine, prednisolone) chemotherapy
Beschrijving

Diffuse Large B-Cell Lymphoma untreated | Rituximab plus CHOP Scheduled | Doxorubicin | Adriamycin | Oncovin | Vincristine | Prednisone | Prednisolone | Follicular Lymphoma untreated | Rituximab plus CVP Scheduled

Datatype

boolean

Alias
UMLS CUI [1,1]
C0079744
UMLS CUI [1,2]
C0332155
UMLS CUI [2,1]
C0393022
UMLS CUI [2,2]
C0332287
UMLS CUI [2,3]
C0163868
UMLS CUI [2,4]
C0205539
UMLS CUI [3]
C0013089
UMLS CUI [4]
C0085752
UMLS CUI [5]
C0591904
UMLS CUI [6]
C0042679
UMLS CUI [7]
C0032952
UMLS CUI [8]
C0032950
UMLS CUI [9,1]
C0024301
UMLS CUI [9,2]
C0332155
UMLS CUI [10,1]
C0393022
UMLS CUI [10,2]
C0332287
UMLS CUI [10,3]
C0056633
UMLS CUI [10,4]
C0205539
eastern cooperative oncology group (ecog) performance status 0-2
Beschrijving

ECOG performance status

Datatype

boolean

Alias
UMLS CUI [1]
C1520224
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
* clinically significant cardiovascular disease (eg, uncontrolled hypertension, myocardial infarction, unstable angina), new york heart association (nyha) classification grade ii or greater congestive heart failure, a ventricular arrhythmia requiring medication within 1 year prior to day 1, or nyha grade ii or greater peripheral vascular disease on day 1 (first day of treatment)
Beschrijving

Cardiovascular Disease | Uncontrolled hypertension | Myocardial Infarction | Angina, Unstable | Congestive heart failure New York Heart Association Classification | Ventricular arrhythmia Requirement Pharmaceutical Preparations | Peripheral Vascular Disease New York Heart Association Classification

Datatype

boolean

Alias
UMLS CUI [1]
C0007222
UMLS CUI [2]
C1868885
UMLS CUI [3]
C0027051
UMLS CUI [4]
C0002965
UMLS CUI [5,1]
C0018802
UMLS CUI [5,2]
C1275491
UMLS CUI [6,1]
C0085612
UMLS CUI [6,2]
C1514873
UMLS CUI [6,3]
C0013227
UMLS CUI [7,1]
C0085096
UMLS CUI [7,2]
C1275491
patients who meet any of the following criteria will be excluded from further study participation after cycle 1:
Beschrijving

Criteria Fulfill | Study Subject Participation Status Excluded

Datatype

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C1550543
UMLS CUI [2,1]
C2348568
UMLS CUI [2,2]
C0332196
circulating lymphocyte count > 5,000/μl before the cycle 2 rituximab infusion
Beschrijving

Circulating Lymphocyte Count

Datatype

boolean

Alias
UMLS CUI [1,1]
C0175630
UMLS CUI [1,2]
C0200635
development of a serious and/or grade 3 or 4 adverse event during cycle 1 judged by the investigator to be related to the rituximab infusion
Beschrijving

Adverse event Serious | Adverse event CTCAE Grades | Relationship Rituximab Infusion

Datatype

boolean

Alias
UMLS CUI [1,1]
C0877248
UMLS CUI [1,2]
C0205404
UMLS CUI [2,1]
C0877248
UMLS CUI [2,2]
C1516728
UMLS CUI [3,1]
C0439849
UMLS CUI [3,2]
C0393022
UMLS CUI [3,3]
C0574032
prior premedication with additional corticosteroids other than the prednisone included in the chemotherapy regimens
Beschrijving

Premedication Adrenal Cortex Hormones Additional | Exception Prednisone

Datatype

boolean

Alias
UMLS CUI [1,1]
C0033045
UMLS CUI [1,2]
C0001617
UMLS CUI [1,3]
C1524062
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0032952
Terug naar het begin van de pagina

Similar models

Eligibility Non-Hodgkin's Lymphoma NCT00719472

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
written informed consent
boolean
C0021430 (UMLS CUI [1])
Age
Item
age ≥ 18 years
boolean
C0001779 (UMLS CUI [1])
Diffuse Large B-Cell Lymphoma untreated | Rituximab plus CHOP Scheduled | Doxorubicin | Adriamycin | Oncovin | Vincristine | Prednisone | Prednisolone | Follicular Lymphoma untreated | Rituximab plus CVP Scheduled
Item
patients with previously untreated diffuse large b-cell lymphoma (dlbcl) who are scheduled to receive rituximab 375 mg/m^2 plus chop (cyclophosphamide, hydroxydaunorubicin [also called doxorubicin or adriamycin], oncovin [vincristine], prednisone or prednisolone) chemotherapy, or previously untreated follicular non-hodgkin lymphoma (nhl) who are scheduled to receive rituximab 375 mg/m^2 plus cvp (cyclophosphamide, vincristine, prednisolone) chemotherapy
boolean
C0079744 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
C0393022 (UMLS CUI [2,1])
C0332287 (UMLS CUI [2,2])
C0163868 (UMLS CUI [2,3])
C0205539 (UMLS CUI [2,4])
C0013089 (UMLS CUI [3])
C0085752 (UMLS CUI [4])
C0591904 (UMLS CUI [5])
C0042679 (UMLS CUI [6])
C0032952 (UMLS CUI [7])
C0032950 (UMLS CUI [8])
C0024301 (UMLS CUI [9,1])
C0332155 (UMLS CUI [9,2])
C0393022 (UMLS CUI [10,1])
C0332287 (UMLS CUI [10,2])
C0056633 (UMLS CUI [10,3])
C0205539 (UMLS CUI [10,4])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status 0-2
boolean
C1520224 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Cardiovascular Disease | Uncontrolled hypertension | Myocardial Infarction | Angina, Unstable | Congestive heart failure New York Heart Association Classification | Ventricular arrhythmia Requirement Pharmaceutical Preparations | Peripheral Vascular Disease New York Heart Association Classification
Item
* clinically significant cardiovascular disease (eg, uncontrolled hypertension, myocardial infarction, unstable angina), new york heart association (nyha) classification grade ii or greater congestive heart failure, a ventricular arrhythmia requiring medication within 1 year prior to day 1, or nyha grade ii or greater peripheral vascular disease on day 1 (first day of treatment)
boolean
C0007222 (UMLS CUI [1])
C1868885 (UMLS CUI [2])
C0027051 (UMLS CUI [3])
C0002965 (UMLS CUI [4])
C0018802 (UMLS CUI [5,1])
C1275491 (UMLS CUI [5,2])
C0085612 (UMLS CUI [6,1])
C1514873 (UMLS CUI [6,2])
C0013227 (UMLS CUI [6,3])
C0085096 (UMLS CUI [7,1])
C1275491 (UMLS CUI [7,2])
Criteria Fulfill | Study Subject Participation Status Excluded
Item
patients who meet any of the following criteria will be excluded from further study participation after cycle 1:
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
C2348568 (UMLS CUI [2,1])
C0332196 (UMLS CUI [2,2])
Circulating Lymphocyte Count
Item
circulating lymphocyte count > 5,000/μl before the cycle 2 rituximab infusion
boolean
C0175630 (UMLS CUI [1,1])
C0200635 (UMLS CUI [1,2])
Adverse event Serious | Adverse event CTCAE Grades | Relationship Rituximab Infusion
Item
development of a serious and/or grade 3 or 4 adverse event during cycle 1 judged by the investigator to be related to the rituximab infusion
boolean
C0877248 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0877248 (UMLS CUI [2,1])
C1516728 (UMLS CUI [2,2])
C0439849 (UMLS CUI [3,1])
C0393022 (UMLS CUI [3,2])
C0574032 (UMLS CUI [3,3])
Premedication Adrenal Cortex Hormones Additional | Exception Prednisone
Item
prior premedication with additional corticosteroids other than the prednisone included in the chemotherapy regimens
boolean
C0033045 (UMLS CUI [1,1])
C0001617 (UMLS CUI [1,2])
C1524062 (UMLS CUI [1,3])
C1705847 (UMLS CUI [2,1])
C0032952 (UMLS CUI [2,2])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial